SCI Abstract

search
+
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study
Volume 200, September 2025, Pages 72-79Author links open overlay panel, , , , , , , , , , Highlights•Perioperative outcome...
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage
ObjectivesThe role of mismatch repair deficiency (MMRd) or DNA damage & response (DDR) mechanisms in general are under...
The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation
Brachytherapy is an important component in the multi-modality definitive treatment for cervical cancer and other recurrent...
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
Patients with epithelial ovarian cancer (EOC) have poor outcomes; most tumors will relapse within several years and develo...
Enhancing predictive accuracy: Assessing the laparoscopic hysterectomy readmission score in a diverse endometrial cancer population
Uterine cancer, the most prevalent form of which is endometrial cancer (EC), is the most commonly diagnosed female reprodu...
Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group
Cervical cancer incidence worldwide is expected to decline with the widespread adoption of human papillomavirus (HPV) vacc...
Impact of chemotherapy provider specialty on outcomes in ovarian cancer
Ovarian cancer (OC) is the second most common gynecologic malignancy in the United States but it carries the worst prognos...
Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases
Low-grade serous ovarian carcinoma (LGSOC) and high-grade serous ovarian carcinoma (HGSOC) represent two different entitie...
Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019
Endometrial cancer incidence and mortality rates have increased significantly among women in the U.S [1,2]. These increase...
Analysis of the use of prophylactic ureteral stents in preventing iatrogenic ureteral injury during radical hysterectomy for cervical Cancer
Cervical cancer ranks as the fourth most common malignancy and cause of cancer-related mortality among women globally [1]....
The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer
Volume 200, September 2025, Pages 145-154Author links open overlay panel, , , , , , , , , , , Highlights•NSMP endometrial ...
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer
Ovarian cancer is the most lethal gynecologic malignancy and accounts for the highest mortality among gynecological cancer...
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
Ovarian cancer is a heterogeneous disease, with subtypes classified by site of origin, pathology, histologic grade, cell s...
Evaluation of the significance of isolated tumor cells in gynecological cancers
The principle of sentinel lymph node (SLN) biopsy is to identify a small number of lymph nodes that have the greatest risk...
HER2 expression in an endometrial cancer cohort
Endometrial cancer (EC) is the most common gynecologic malignancy in women with an estimated 67,880 new cases to be diagno...
Optimizing the screening and management of preoperative anemia prior to gynecologic oncology surgery (OPRA1): A quality improvement initiative
Anemia is a common, yet preventable condition in patients with cancer. The World Health Organization (WHO) describes anemi...
Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database
Epithelial Ovarian Cancer (EOC) is the second most deadly gynecologic cancer and the third most common cancer worldwide [1...
Beating cancer while building families: A mixed methods study on parenting, life choices, and career trajectories of gynecologic oncologists in the United States
The path to become a fully trained physician parallels the time when major life events, such as long-term partnership and ...
Effect of conization, manipulator use, and their interaction on recurrence after radical hysterectomy for cervical cancer: A multicenter retrospective analysis
Historically, open surgery has been the standard approach for radical hysterectomy in patients with early cervical cancer,...
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
Approximately 5 % of invasive breast cancers are attributable to a germline pathogenic variant (herein referred to as muta...
An absence of translated consent forms limits oncologic clinical trial enrollment for limited English proficiency participants
An absence of translated consent forms limits oncologic clinical trial enrollment for limited English proficiency participants
Volume 180, January 2024, Pages 86-90Author links open overlay panel, , , , AbstractObjectivesA lack of diversity amongst ...
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma
KeywordsHomologous-recombination-deficiency (HRD)High-grade serous ovarian cancer (HGSC)Whole-genome-sequencing (WGS)Genet...
Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts
Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts
Approximately one in four cervical cancer patients suffers from recurrence following primary treatment [1]. Even patients ...
Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US
Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US
Worldwide, cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related dea...
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma
N. Colombo et al.ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-upRadiother. ...
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting
Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting
Ovarian cancer accounts for 1.0% of all cancers and is the fifth leading cause of cancer-related death in women [1]. It is...
Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer
Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer
Management of menopausal symptoms in patients with uterine cancer remains clinically challenging [1,2]. As uterine cancer ...
Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement
Management and long-term clinical outcomes of patients with stage IVA cervical cancer with bladder involvement
The most locally advanced International Federation of Gynecology and Obstetrics (FIGO) stage of cervical cancer is IVA dis...
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival
Ovarian cancer (OC), specifically high-grade serous ovarian cancer (HGSOC), is characterized by deficiencies in homologous...
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions
Human epidermal growth factor receptor 2 (HER2) is tyrosine kinase receptor encoded by the ERBB2 gene [1]. ERBB2 amplifica...
Load More
format_indent_increase